{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:42:24Z","timestamp":1794541344708,"version":"4.9.1"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sichuan Science and Technology Program","award":["2025ZNSFSC0987"],"award-info":[{"award-number":["2025ZNSFSC0987"]}]},{"name":"Sichuan Science and Technology Program","award":["2024NSFJQ0048, 2024NSFTD0024"],"award-info":[{"award-number":["2024NSFJQ0048, 2024NSFTD0024"]}]},{"name":"Research Fund of Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital","award":["24QNPY026"],"award-info":[{"award-number":["24QNPY026"]}]},{"name":"Excellent Young Science Fund for National Natural Science Foundation of China","award":["82022033"],"award-info":[{"award-number":["82022033"]}]},{"name":"The Medical Equipment Management Branch of Sichuan Hospital Association in 2024","award":["SCZB015"],"award-info":[{"award-number":["SCZB015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02700-x","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T11:15:32Z","timestamp":1769685332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Combination therapy strategies in engineered 177Lu radiopharmaceuticals beyond single modality: design principles and application outlet"],"prefix":"10.1186","volume":"24","author":[{"given":"Yi","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobiao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8367-7971","authenticated-orcid":false,"given":"Binxu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6971-1164","authenticated-orcid":false,"given":"Kun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2700_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"2700_CR2","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1016\/S1470-2045(24)00037-8","volume":"25","author":"AM Scott","year":"2024","unstructured":"Scott AM, Zeglis BM, Lapi SE, Scott PJH, Windhorst AD, Abdel-Wahab M, et al. Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics. Lancet Oncol Elsevier. 2024;25:e250\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(24)00037-8.","journal-title":"Lancet Oncol Elsevier"},{"key":"2700_CR3","unstructured":"Targeted therapy in nuclear medicine\u2014current status and future prospects. Ann Oncol. https:\/\/www.annalsofoncology.org\/article\/S0923-7534(19)41132-0\/fulltext. Accessed 2 Apr 2025. Cited 2025 Apr 2."},{"key":"2700_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S1470-2045(05)01737-7","volume":"6","author":"SM Bentzen","year":"2005","unstructured":"Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol Elsevier. 2005;6:112\u20137. https:\/\/doi.org\/10.1016\/S1470-2045(05)01737-7.","journal-title":"Lancet Oncol Elsevier"},{"key":"2700_CR5","doi-asserted-by":"publisher","first-page":"12004","DOI":"10.1021\/acs.chemrev.3c00456","volume":"123","author":"KA Morgan","year":"2023","unstructured":"Morgan KA, Rudd SE, Noor A, Donnelly PS. Theranostic nuclear medicine with Gallium-68, Lutetium-177, Copper-64\/67, Actinium-225, and Lead-212\/203 radionuclides. Chem Rev Am Chem Soc. 2023;123:12004\u201335. https:\/\/doi.org\/10.1021\/acs.chemrev.3c00456.","journal-title":"Chem Rev Am Chem Soc"},{"key":"2700_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s12149-023-01839-8","volume":"37","author":"S Molavipordanjani","year":"2023","unstructured":"Molavipordanjani S, Mousavi T, Khorramimoghaddam A, Talebpour Amiri F, Abedi SM, Hosseinimehr SJ. The preclinical study of 177Lu-DOTA-LTVSPWY as a potential therapeutic agent against HER2 overexpressed cancer. Ann Nucl Med. 2023;37:400\u20139. https:\/\/doi.org\/10.1007\/s12149-023-01839-8.","journal-title":"Ann Nucl Med"},{"key":"2700_CR7","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1021\/cr500171e","volume":"115","author":"S Banerjee","year":"2015","unstructured":"Banerjee S, Pillai MRA, Knapp FF (Russ). Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev Am Chem Soc. 2015;115:2934\u201374. https:\/\/doi.org\/10.1021\/cr500171e","journal-title":"Chem Rev Am Chem Soc"},{"key":"2700_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/ph12030114","volume":"12","author":"U Hennrich","year":"2019","unstructured":"Hennrich U, Kopka K, Lutathera\u00ae. The first FDA- and EMA-Approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals (Basel). 2019;12:114. https:\/\/doi.org\/10.3390\/ph12030114.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2700_CR9","unstructured":"[177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/38467922\/. Accessed 22 Oct 2024.\u00a0Cited 2024 Oct 22."},{"key":"2700_CR10","doi-asserted-by":"publisher","first-page":"e258","DOI":"10.1097\/RLU.0000000000005208","volume":"49","author":"Y Rathore","year":"2024","unstructured":"Rathore Y, Lakhanpal T, Chakraborty S, Chakravarty R, Mittal BR, Irrinki RNS, et al. Targeting breast cancer using 177 Lu-Labeled trastuzumab and trastuzumab fragment : first-in-human clinical experience. Clin Nucl Med. 2024;49:e258\u201365. https:\/\/doi.org\/10.1097\/RLU.0000000000005208.","journal-title":"Clin Nucl Med"},{"key":"2700_CR11","unstructured":"177 Lu-DOTATATE (Lutathera) Therapy in 68 Ga-DOTATATE PET\/CT-Negative Liver Metastases of a Neuroendocrine Tumor. PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/37883194\/. Accessed 22 Oct 2024.\u00a0Cited 2024 Oct 22."},{"key":"2700_CR12","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1016\/S1470-2045(17)30379-0","volume":"18","author":"MR Gill","year":"2017","unstructured":"Gill MR, Falzone N, Du Y, Vallis KA. Targeted radionuclide therapy in combined-modality regimens. Lancet Oncol Elsevier. 2017;18:e414\u201323. https:\/\/doi.org\/10.1016\/S1470-2045(17)30379-0.","journal-title":"Lancet Oncol Elsevier"},{"key":"2700_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13045-021-01171-6","volume":"14","author":"E Duray","year":"2021","unstructured":"Duray E, Lejeune M, Baron F, Beguin Y, Devoogdt N, Krasniqi A, et al. A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma. J Hematol Oncol. 2021;14:183. https:\/\/doi.org\/10.1186\/s13045-021-01171-6.","journal-title":"J Hematol Oncol"},{"key":"2700_CR14","doi-asserted-by":"publisher","first-page":"6415","DOI":"10.1039\/C5CS00784D","volume":"45","author":"M Patra","year":"2016","unstructured":"Patra M, Zarschler K, Pietzsch H-J, Stephan H, Gasser G. New insights into the pretargeting approach to image and treat tumours. Chem Soc Rev Royal Soc Chem. 2016;45:6415\u201331. https:\/\/doi.org\/10.1039\/C5CS00784D.","journal-title":"Chem Soc Rev Royal Soc Chem"},{"key":"2700_CR15","doi-asserted-by":"publisher","first-page":"2001879","DOI":"10.1002\/advs.202001879","volume":"8","author":"L Kang","year":"2021","unstructured":"Kang L, Li C, Rosenkrans ZT, Huo N, Chen Z, Ehlerding EB, et al. CD38-Targeted theranostics of lymphoma with 89Zr\/177Lu\u2010Labeled daratumumab. Adv Sci (Weinh). 2021;8:2001879. https:\/\/doi.org\/10.1002\/advs.202001879.","journal-title":"Adv Sci (Weinh)"},{"key":"2700_CR16","first-page":"s5729","volume":"55","author":"DJ Buchsbaum","year":"1995","unstructured":"Buchsbaum DJ. Experimental approaches to increase radiolabeled antibody localization in tumors. Cancer Res. 1995;55:s5729\u201332.","journal-title":"Cancer Res"},{"key":"2700_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1089\/cbr.2023.0108","volume":"39","author":"R Sharma","year":"2024","unstructured":"Sharma R, Mukherjee A, Kumar A, Sarma HD. Evaluation of177 Lu-labeled Pertuzumab F(ab\u2032)2 fragments for HER2-positive cancer targeting: a comparative in vitro and in vivo study. Cancer Biother Radiopharm. 2024;39:64\u201374. https:\/\/doi.org\/10.1089\/cbr.2023.0108.","journal-title":"Cancer Biother Radiopharm"},{"key":"2700_CR18","doi-asserted-by":"publisher","first-page":"LBA588","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA588","volume":"42","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin DM, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: primary analysis of the phase 3 randomized NETTER-2 study. J Clin Oncol Wolters Kluwer. 2024;42:LBA588\u2013588. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.LBA588.","journal-title":"J Clin Oncol Wolters Kluwer"},{"key":"2700_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/med.20002","volume":"24","author":"Sm Okarvi","year":"2004","unstructured":"Okarvi Sm. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev. 2004;24:357\u201397. https:\/\/doi.org\/10.1002\/med.20002.","journal-title":"Med Res Rev"},{"key":"2700_CR20","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1210\/clinem\/dgac574","volume":"107","author":"J Hofland","year":"2022","unstructured":"Hofland J, Brabander T, Verburg FA, Feelders RA, de Herder WW. Peptide receptor radionuclide therapy. J Clin Endocrinol Metab. 2022;107:3199\u2013208. https:\/\/doi.org\/10.1210\/clinem\/dgac574.","journal-title":"J Clin Endocrinol Metab"},{"key":"2700_CR21","doi-asserted-by":"publisher","first-page":"118206","DOI":"10.1016\/j.lfs.2020.118206","volume":"258","author":"N Mohtavinejad","year":"2020","unstructured":"Mohtavinejad N, Shafiee Ardestani M, Khalaj A, Pormohammad A, Najafi R, Bitarafan-Rajabi A, et al. Application of radiolabeled peptides in tumor imaging and therapy. Life Sci. 2020;258:118206. https:\/\/doi.org\/10.1016\/j.lfs.2020.118206.","journal-title":"Life Sci"},{"key":"2700_CR22","doi-asserted-by":"publisher","first-page":"102862","DOI":"10.1016\/j.eclinm.2024.102862","volume":"77","author":"K Herrmann","year":"2024","unstructured":"Herrmann K, Gafita A, de Bono JS, Sartor O, Chi KN, Krause BJ, et al. Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial. eClinicalMedicine. 2024;77:102862. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102862.","journal-title":"eClinicalMedicine"},{"key":"2700_CR23","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, De Bono JS, Shore ND, Chi KN, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404:1227\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(24)01653-2.","journal-title":"Lancet"},{"key":"2700_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus Cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"key":"2700_CR25","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00259-023-06561-1","volume":"51","author":"Z Zeng","year":"2024","unstructured":"Zeng Z, Li L, Tao J, Liu J, Li H, Qian X, et al. [177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models. Eur J Nucl Med Mol Imaging. 2024;51:1221\u201332. https:\/\/doi.org\/10.1007\/s00259-023-06561-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2700_CR26","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.3390\/cells11192983","volume":"11","author":"A Hull","year":"2022","unstructured":"Hull A, Li Y, Bartholomeusz D, Hsieh W, Tieu W, Pukala TL, et al. Preliminary development and testing of C595 radioimmunoconjugates for targeting MUC1 cancer epitopes in pancreatic ductal adenocarcinoma. Cells. 2022;11:2983. https:\/\/doi.org\/10.3390\/cells11192983.","journal-title":"Cells"},{"key":"2700_CR27","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1039\/C3CC38507H","volume":"49","author":"GJ Stasiuk","year":"2013","unstructured":"Stasiuk GJ, Long NJ. The ubiquitous DOTA and its derivatives: the impact of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid on biomedical imaging. Chem Commun Royal Soc Chem. 2013;49:2732\u201346. https:\/\/doi.org\/10.1039\/C3CC38507H.","journal-title":"Chem Commun Royal Soc Chem"},{"key":"2700_CR28","doi-asserted-by":"publisher","first-page":"e2203820119","DOI":"10.1073\/pnas.2203820119","volume":"119","author":"JA Korsen","year":"2022","unstructured":"Korsen JA, Gutierrez JA, Tully KM, Carter LM, Samuels ZV, Khitrov S, et al. Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer. Proc Natl Acad Sci U S A. 2022;119:e2203820119. https:\/\/doi.org\/10.1073\/pnas.2203820119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2700_CR29","doi-asserted-by":"publisher","first-page":"8670","DOI":"10.1021\/ja3024725","volume":"134","author":"EW Price","year":"2012","unstructured":"Price EW, Cawthray JF, Ferreira CL, Boros E, Adam MJ, Orvig C. H4octapa: an acyclic chelator for 111In radiopharmaceuticals. J Am Chem Soc Am Chem Soc. 2012;134:8670\u201383. https:\/\/doi.org\/10.1021\/ja3024725.","journal-title":"J Am Chem Soc Am Chem Soc"},{"key":"2700_CR30","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1038\/s41467-023-36377-4","volume":"14","author":"J Rong","year":"2023","unstructured":"Rong J, Haider A, Jeppesen TE, Josephson L, Liang SH. Radiochemistry for positron emission tomography. Nat Commun. 2023;14:3257. https:\/\/doi.org\/10.1038\/s41467-023-36377-4.","journal-title":"Nat Commun"},{"key":"2700_CR31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00259-022-05954-y","volume":"50","author":"C Li","year":"2022","unstructured":"Li C, Liu J, Yang X, Yang Q, Huang W, Zhang M, et al. Theranostic application of 64Cu\/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models. Eur J Nucl Med Mol Imaging. 2022;50:168\u201383. https:\/\/doi.org\/10.1007\/s00259-022-05954-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2700_CR32","doi-asserted-by":"publisher","unstructured":"Lewis MR, Raubitschek A, Shively JE, Facile A. Water-Soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. ACS Publications. American Chemical Society; 2002. https:\/\/doi.org\/10.1021\/bc00030a012.\u00a0Cited 2025 Oct 15.","DOI":"10.1021\/bc00030a012"},{"key":"2700_CR33","unstructured":"Radioactive labeling of antibody: a simple and efficient method. Science. https:\/\/www.science.org\/doi\/abs\/10.1126\/science.6836304. Accessed 15 Oct 2025.\u00a0Cited 2025 Oct 15."},{"key":"2700_CR34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.eururo.2015.11.033","volume":"69","author":"CHJ Muselaers","year":"2016","unstructured":"Muselaers CHJ, Boers-Sonderen MJ, van Oostenbrugge TJ, Boerman OC, Desar IME, Stillebroer AB, et al. Phase 2 study of lutetium 177\u2013Labeled Anti\u2013Carbonic anhydrase IX monoclonal antibody Girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2016;69:767\u201370. https:\/\/doi.org\/10.1016\/j.eururo.2015.11.033.","journal-title":"Eur Urol"},{"key":"2700_CR35","unstructured":"Phase II study of Lutetium-177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. J Clin Oncol. https:\/\/ascopubs.org\/doi\/abs\/10.1200\/jco.2015.33.15_suppl.e14014. Accessed 23 Mar 2025.\u00a0Cited 2025 Mar 23."},{"key":"2700_CR36","unstructured":"Phase I\/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2019.37.7_suppl.TPS339. Accessed 23 Mar 2025.\u00a0Cited 2025 Mar 23."},{"key":"2700_CR37","doi-asserted-by":"crossref","unstructured":"[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. https:\/\/www.mdpi.com\/1424-8247\/15\/10\/1292. Accessed 24 Mar 2025.\u00a0Cited 2025 Mar 24.","DOI":"10.3390\/ph15101292"},{"key":"2700_CR38","unstructured":"A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer. Eur J Nuclear Med Mol Imaging. https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06470-3. Accessed 24 Mar 2025.\u00a0Cited 2025 Mar 24."},{"key":"2700_CR39","unstructured":"Lu-177-Labeled Hetero-Bivalent Agents Targeting PSMA and Bone Metastases for Radionuclide Therapy. J Med Chem. https:\/\/pubs.acs.org\/doi\/abs\/10.1021\/acs.jmedchem.3c01294?casa_token=LHqnOFsZ1I4AAAAA:yr6YqxiwK7k4uFzwH9RkuhieMPeDJBoMc-MhOqtjRzWr0KrE66UTVcA9o2_kNA6zFh2DiFXoIv4L9RcM&casa_token=DINgUrUPAv8AAAAA:ciLrx-e85xpbX08nv-0b1DCc8DXAGFHtshCaDSe2GUZXXJRjHJj39bI1q2dboVMUQNfm1YhlddJKDfKF. Accessed 12 July 2025. Cited 2025 July 12."},{"key":"2700_CR40","unstructured":"Theranostic trial of well differentiated neuroendocrine tumors (NETs) with somatostatin antagonists 68Ga-OPS202 and 177Lu-OPS201. J Clin Oncol. https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2017.35.15_suppl.4094. Accessed 24 Mar 2025.\u00a0Cited 2025 Mar 24."},{"key":"2700_CR41","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1007\/s00259-024-06682-1","volume":"51","author":"SB Sch\u00fcrrle","year":"2024","unstructured":"Sch\u00fcrrle SB, Eberlein U, Ansquer C, Beauregard J-M, Durand-Gasselin L, Gr\u00f8nb\u00e6k H, et al. Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2024;51:2428\u201341. https:\/\/doi.org\/10.1007\/s00259-024-06682-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2700_CR42","doi-asserted-by":"publisher","first-page":"520","DOI":"10.2967\/jnumed.119.233031","volume":"61","author":"C Rottenburger","year":"2020","unstructured":"Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, et al. Cholecystokinin 2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma: results of the lumed phase 0a study. J Nucl Med. 2020;61:520\u20136. https:\/\/doi.org\/10.2967\/jnumed.119.233031.","journal-title":"J Nucl Med"},{"key":"2700_CR43","doi-asserted-by":"publisher","first-page":"S528","DOI":"10.1016\/j.annonc.2021.08.044","volume":"32","author":"S Khatua","year":"2021","unstructured":"Khatua S, D\u00fcring M, Lind CL, Nielsen JR. 380TiP A phase I\/II dose-escalation and expansion cohort study of intracerebroventricular radioimmunotherapy using 177Lu-DTPA-omburtamab in pediatric and adolescent patients with recurrent or refractory Medulloblastoma. Annals Oncol Elsevier. 2021;32:S528\u20139. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.044.","journal-title":"Annals Oncol Elsevier"},{"key":"2700_CR44","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s00259-023-06169-5","volume":"50","author":"T Yang","year":"2023","unstructured":"Yang T, Peng L, Qiu J, He X, Zhang D, Wu R, et al. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy. Eur J Nucl Med Mol Imaging. 2023;50:2331\u201341. https:\/\/doi.org\/10.1007\/s00259-023-06169-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2700_CR45","doi-asserted-by":"publisher","first-page":"12382","DOI":"10.3390\/ijms241512382","volume":"24","author":"M Luna-Guti\u00e9rrez","year":"2023","unstructured":"Luna-Guti\u00e9rrez M, Cruz-Nova P, Jim\u00e9nez-Mancilla N, Oros-Pantoja R, Lara-Almaz\u00e1n N, Santos-Cuevas C, et al. Synthesis and evaluation of 177Lu-DOTA-PD-L1-i and 225Ac-HEHA-PD-L1-i as potential radiopharmaceuticals for tumor Microenvironment-Targeted radiotherapy. Int J Mol Sci. 2023;24:12382. https:\/\/doi.org\/10.3390\/ijms241512382.","journal-title":"Int J Mol Sci"},{"key":"2700_CR46","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1021\/acs.molpharmaceut.4c00095","volume":"21","author":"MD Pun","year":"2024","unstructured":"Pun MD, Gallazzi F, Ho K-V, Watkinson L, Carmack TL, Iweha E, et al. Albumin-Binding Lutetium-177-Labeled LLP2A derivatives as theranostics for melanoma. Mol Pharm. 2024;21:2960\u20139. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00095.","journal-title":"Mol Pharm"},{"key":"2700_CR47","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/14737140.2023.2213892","volume":"23","author":"K Patell","year":"2023","unstructured":"Patell K, Kurian M, Garcia JA, Mendiratta P, Barata PC, Jia AY, et al. Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review. Expert Rev Anticancer Ther. 2023;23:731\u201344. https:\/\/doi.org\/10.1080\/14737140.2023.2213892.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2700_CR48","doi-asserted-by":"publisher","first-page":"82","DOI":"10.36000\/hbT.OH.2021.08.041","volume":"8","author":"A Meisel","year":"2021","unstructured":"Meisel A. Prostate cancer highlights from ASCO GU 2021: cutting-edge results. healthbook TIMES Onco Hema. The Healthbook Company LTD. 2021;8:82\u20134. https:\/\/doi.org\/10.36000\/hbT.OH.2021.08.041.","journal-title":"The Healthbook Company LTD"},{"key":"2700_CR49","unstructured":"177Lu-Dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(21)00572-6\/abstract. Accessed 20 Nov 2025. Cited 2025 Nov 20."},{"key":"2700_CR50","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1097\/RLU.0000000000004929","volume":"49","author":"MP Yadav","year":"2024","unstructured":"Yadav MP, Raju S, Ballal S, Bal C. Complete response to 177Lu-DOTATATE PRRT in a 9-Year-Old child with metastatic carotid body paraganglioma. Clin Nucl Med. 2024;49:e33\u20134. https:\/\/doi.org\/10.1097\/RLU.0000000000004929.","journal-title":"Clin Nucl Med"},{"key":"2700_CR51","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"2700_CR52","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752\u201363. https:\/\/doi.org\/10.1016\/S1470-2045(21)00572-6.","journal-title":"Lancet Oncol"},{"key":"2700_CR53","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","volume":"26","author":"L Emmett","year":"2025","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Joshua AM, Sandhu S, Nguyen A, et al. Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol Elsevier. 2025;26:291\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(25)00009-9.","journal-title":"Lancet Oncol Elsevier"},{"key":"2700_CR54","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2967\/jnumed.123.267321","volume":"65","author":"R Seifert","year":"2024","unstructured":"Seifert R, Telli T, Lapa C, Desaulniers M, Hekimsoy T, Weber WA, et al. Safety and efficacy of extended therapy with [177 Lu]Lu-PSMA: a German multicenter study. J Nucl Med. 2024;65:909\u201316. https:\/\/doi.org\/10.2967\/jnumed.123.267321.","journal-title":"J Nucl Med"},{"key":"2700_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/RLU.0000000000005573","volume":"50","author":"T Xu","year":"2025","unstructured":"Xu T, Wang Y, Liu G, Li H, Qu G, Zhang X, et al. Efficacy and safety of 177Lu-DOTA-IBA in tumor bone metastasis treatment: A prospective clinical trial. Clin Nucl Med. 2025;50:119\u201324. https:\/\/doi.org\/10.1097\/RLU.0000000000005573.","journal-title":"Clin Nucl Med"},{"key":"2700_CR56","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.7150\/thno.107963","volume":"15","author":"H Dadgar","year":"2025","unstructured":"Dadgar H, Pashazadeh A, Norouzbeigi N, Assadi M, Al-Balooshi B, Baum RP, et al. Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177Lu\/225Ac treatment in neuroendocrine tumors and metastatic prostate cancer. Theranostics. 2025;15:4368\u201397. https:\/\/doi.org\/10.7150\/thno.107963.","journal-title":"Theranostics"},{"key":"2700_CR57","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1089\/cbr.2023.0195","volume":"39","author":"J Dubois","year":"2024","unstructured":"Dubois J, Tosato G, Garrigue P, Taieb D, Guillet B, Nail V. Short-term biological toxicity prediction of [177 Lu]lutetium-oxodotreotide: an original retrospective analysis. Cancer Biother Radiopharm. 2024;39:381\u20139. https:\/\/doi.org\/10.1089\/cbr.2023.0195.","journal-title":"Cancer Biother Radiopharm"},{"key":"2700_CR58","doi-asserted-by":"publisher","first-page":"20201041","DOI":"10.1259\/bjr.20201041","volume":"94","author":"K Sitani","year":"2021","unstructured":"Sitani K, Parghane RV, Talole S, Basu S. Long-term outcome of Indigenous 177Lu-DOTATATE PRRT in patients with metastatic advanced neuroendocrine tumours: a single institutional observation in a large tertiary care setting. Br J Radiol. 2021;94:20201041. https:\/\/doi.org\/10.1259\/bjr.20201041.","journal-title":"Br J Radiol"},{"key":"2700_CR59","doi-asserted-by":"publisher","first-page":"6290","DOI":"10.3390\/cancers13246290","volume":"13","author":"D Theiler","year":"2021","unstructured":"Theiler D, Cattaneo M, Dierickx LO, Igaz P, Grozinsky-Glasberg S, Bournaud C, et al. Safety and efficacy of peptide-receptor radionuclide therapy in elderly neuroendocrine tumor patients. Cancers. 2021;13:6290. https:\/\/doi.org\/10.3390\/cancers13246290.","journal-title":"Cancers"},{"key":"2700_CR60","doi-asserted-by":"publisher","first-page":"451","DOI":"10.7150\/thno.92487","volume":"14","author":"RP Baum","year":"2024","unstructured":"Baum RP, Fan X, Jakobsson V, Yu F, Schuchardt C, Chen X, et al. Long-term nephrotoxicity after PRRT: myth or reality. Theranostics. 2024;14:451\u20139. https:\/\/doi.org\/10.7150\/thno.92487.","journal-title":"Theranostics"},{"key":"2700_CR61","first-page":"S13","volume":"46","author":"M de Jong","year":"2005","unstructured":"de Jong M, Breeman WAP, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-Labeled somatostatin analogs. J Nuclear Med Soc Nuclear Med. 2005;46:S13\u20137.","journal-title":"J Nuclear Med Soc Nuclear Med"},{"key":"2700_CR62","doi-asserted-by":"publisher","first-page":"1218670","DOI":"10.3389\/fchem.2023.1218670","volume":"11","author":"SC George","year":"2023","unstructured":"George SC, Samuel EJJ. Developments in 177Lu-based radiopharmaceutical therapy and dosimetry. Front Chem. 2023;11:1218670. https:\/\/doi.org\/10.3389\/fchem.2023.1218670.","journal-title":"Front Chem"},{"key":"2700_CR63","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40336-025-00685-0","volume":"13","author":"A Di Dia","year":"2025","unstructured":"Di Dia A, Ferrari ME, Travaini LL, Grappeja L, Guglielmo P, Barone A, et al. The value of dosimetry in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors: literature and practical aspects. Clin Transl Imaging. 2025;13:121\u20139. https:\/\/doi.org\/10.1007\/s40336-025-00685-0.","journal-title":"Clin Transl Imaging"},{"key":"2700_CR64","unstructured":"Spandidos Publications: International Journal of Oncology. https:\/\/www.spandidos-publications.com\/ijo. Accessed 23 Oct 2025.\u00a0Cited 2025 Oct 23."},{"key":"2700_CR65","doi-asserted-by":"crossref","unstructured":"Hypoxia-Induced cancer cell responses driving radioresistance of hypoxic tumors: approaches to targeting and radiosensitizing. https:\/\/www.mdpi.com\/2072-6694\/13\/5\/1102. Accessed 23 Oct 2025.\u00a0Cited 2025 Oct 23.","DOI":"10.3390\/cancers13051102"},{"key":"2700_CR66","doi-asserted-by":"publisher","unstructured":"Park SWS, Fransson S, Sundquist F, Nilsson JN, Gryb\u00e4ck P, Wessman S, et al. Heterogeneous SSTR2 target expression and a novel KIAA1549: BRAF fusion clone in a progressive metastatic lesion following 177Lutetium-DOTATATE molecular radiotherapy in neuroblastoma: a case report. Front Oncol. 2024;14. https:\/\/doi.org\/10.3389\/fonc.2024.1408729.","DOI":"10.3389\/fonc.2024.1408729"},{"key":"2700_CR67","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.3390\/cancers13143607","volume":"13","author":"AD Puranik","year":"2021","unstructured":"Puranik AD, Dromain C, Fleshner N, Sathekge M, Pavel M, Eberhardt N, et al. Target heterogeneity in oncology: the best predictor for differential response to radioligand therapy in neuroendocrine tumors and prostate cancer. Cancers (Basel). 2021;13:3607. https:\/\/doi.org\/10.3390\/cancers13143607.","journal-title":"Cancers (Basel)"},{"key":"2700_CR68","doi-asserted-by":"publisher","first-page":"117829","DOI":"10.1016\/j.ejmech.2025.117829","volume":"296","author":"L Wang","year":"2025","unstructured":"Wang L, Lu C, Wang X, Wu D. PSMA targeted therapy: from molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer. Eur J Med Chem. 2025;296:117829. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117829.","journal-title":"Eur J Med Chem"},{"key":"2700_CR69","unstructured":"Tumour Heterogeneity and the Consequent practical challenges in the management of gastroenteropancreatic neuroendocrine neoplasms. PMC. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10047148\/. Accessed 29 Oct 2025.\u00a0Cited 2025 Oct 29."},{"key":"2700_CR70","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2967\/jnumed.120.259192","volume":"63","author":"RP Baum","year":"2022","unstructured":"Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, et al. Feasibility, Biodistribution, and preliminary dosimetry in Peptide-Targeted radionuclide therapy of diverse adenocarcinomas Using177 Lu-FAP-2286: First-in-Humans results. J Nucl Med. 2022;63:415\u201323. https:\/\/doi.org\/10.2967\/jnumed.120.259192.","journal-title":"J Nucl Med"},{"key":"2700_CR71","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76:469\u201378. https:\/\/doi.org\/10.1016\/j.eururo.2019.06.030.","journal-title":"Eur Urol"},{"key":"2700_CR72","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1007\/s00259-020-05098-x","volume":"48","author":"A L\u00f8ndalen","year":"2021","unstructured":"L\u00f8ndalen A, Blakkisrud J, Revheim M-E, Madsbu UE, Dahle J, Kolstad A, et al. FDG PET\/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab Satetraxetan for treatment of relapsed non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2021;48:1902\u201314. https:\/\/doi.org\/10.1007\/s00259-020-05098-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2700_CR73","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2967\/jnumed.116.173922","volume":"58","author":"J Blakkisrud","year":"2017","unstructured":"Blakkisrud J, L\u00f8ndalen A, Martinsen ACT, Dahle J, Holtedahl JE, Bach-Gansmo T, et al. Tumor-Absorbed dose for Non-Hodgkin lymphoma patients treated with the Anti-CD37 antibody radionuclide conjugate 177Lu-Lilotomab Satetraxetan. J Nuclear Med Soc Nuclear Med. 2017;58:48\u201354. https:\/\/doi.org\/10.2967\/jnumed.116.173922.","journal-title":"J Nuclear Med Soc Nuclear Med"},{"key":"2700_CR74","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.3390\/pharmaceutics15122761","volume":"15","author":"Y Khazaei Monfared","year":"2023","unstructured":"Khazaei Monfared Y, Heidari P, Klempner SJ, Mahmood U, Parikh AR, Hong TS, et al. DNA damage by radiopharmaceuticals and mechanisms of cellular repair. Pharmaceutics. 2023;15:2761. https:\/\/doi.org\/10.3390\/pharmaceutics15122761.","journal-title":"Pharmaceutics"},{"key":"2700_CR75","doi-asserted-by":"publisher","first-page":"10196","DOI":"10.1038\/s41598-020-67199-9","volume":"10","author":"C Cullinane","year":"2020","unstructured":"Cullinane C, Waldeck K, Kirby L, Rogers BE, Eu P, Tothill RW, et al. Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP. Sci Rep. 2020;10:10196. https:\/\/doi.org\/10.1038\/s41598-020-67199-9.","journal-title":"Sci Rep"},{"key":"2700_CR76","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.3390\/cancers13143429","volume":"13","author":"G Birindelli","year":"2021","unstructured":"Birindelli G, Drobnjakovic M, Morath V, Steiger K, D\u2019Alessandria C, Gourni E, et al. Is hypoxia a factor influencing PSMA-directed radioligand therapy?\u2014an in Silico study on the role of chronic hypoxia in prostate cancer. Cancers. 2021;13:3429. https:\/\/doi.org\/10.3390\/cancers13143429.","journal-title":"Cancers"},{"key":"2700_CR77","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.3390\/pharmaceutics15122761","volume":"15","author":"Y Khazaei Monfared","year":"2023","unstructured":"Khazaei Monfared Y, Heidari P, Klempner SJ, Mahmood U, Parikh AR, Hong TS, et al. DNA damage by radiopharmaceuticals and mechanisms of cellular Repair. Pharmaceutics. Multidisciplinary Digit Publishing Inst. 2023;15:2761. https:\/\/doi.org\/10.3390\/pharmaceutics15122761.","journal-title":"Multidisciplinary Digit Publishing Inst"},{"key":"2700_CR78","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","volume":"35","author":"D Olmos","year":"2024","unstructured":"Olmos D, Lorente D, Alameda D, Cattrini C, Romero-Laorden N, Lozano R, et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. Ann Oncol. 2024;35:458\u201372. https:\/\/doi.org\/10.1016\/j.annonc.2024.01.011.","journal-title":"Ann Oncol"},{"key":"2700_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.12.002","volume":"73","author":"E Franzese","year":"2019","unstructured":"Franzese E, Centonze S, Diana A, Carlino F, Guerrera LP, Di Napoli M, et al. PARP inhibitors in ovarian cancer. Cancer Treat Rev. 2019;73:1\u20139. https:\/\/doi.org\/10.1016\/j.ctrv.2018.12.002.","journal-title":"Cancer Treat Rev"},{"key":"2700_CR80","doi-asserted-by":"publisher","first-page":"1331364","DOI":"10.3389\/fnume.2024.1331364","volume":"4","author":"AG Shea","year":"2024","unstructured":"Shea AG, Idrissou MB, Torres AI, Chen T, Hernandez R, Morris ZS, et al. Immunological effects of radiopharmaceutical therapy. Front Nucl Med. 2024;4:1331364. https:\/\/doi.org\/10.3389\/fnume.2024.1331364.","journal-title":"Front Nucl Med"},{"key":"2700_CR81","doi-asserted-by":"publisher","first-page":"961637","DOI":"10.3389\/fonc.2022.961637","volume":"12","author":"G Chen","year":"2022","unstructured":"Chen G, Wu K, Li H, Xia D, He T. Role of hypoxia in the tumor microenvironment and targeted therapy. Front Oncol. 2022;12:961637. https:\/\/doi.org\/10.3389\/fonc.2022.961637.","journal-title":"Front Oncol"},{"key":"2700_CR82","doi-asserted-by":"publisher","first-page":"1568634","DOI":"10.3389\/fcell.2025.1568634","volume":"13","author":"J Chen","year":"2025","unstructured":"Chen J, Wang S, Ding Y, Xu D, Zheng S. Radiotherapy-induced alterations in tumor microenvironment: metabolism and immunity. Front Cell Dev Biol. 2025;13:1568634. https:\/\/doi.org\/10.3389\/fcell.2025.1568634.","journal-title":"Front Cell Dev Biol"},{"key":"2700_CR83","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pharmthera.2018.09.008","volume":"194","author":"A Constantinidou","year":"2019","unstructured":"Constantinidou A, Alifieris C, Trafalis DT. Targeting programmed cell Death\u2009\u2013\u20091 (PD-1) and ligand (PD-L1): A new era in cancer active immunotherapy. Pharmacol Ther. 2019;194:84\u2013106. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.09.008.","journal-title":"Pharmacol Ther"},{"key":"2700_CR84","doi-asserted-by":"publisher","first-page":"e001698","DOI":"10.1136\/jitc-2020-001698","volume":"9","author":"Z Yin","year":"2021","unstructured":"Yin Z, Yu M, Ma T, Zhang C, Huang S, Karimzadeh MR, et al. Mechanisms underlying low-clinical responses to PD-1\/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of Exosomal PD-L1. J Immunother Cancer. 2021;9:e001698. https:\/\/doi.org\/10.1136\/jitc-2020-001698.","journal-title":"J Immunother Cancer"},{"key":"2700_CR85","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","volume":"9","author":"L Zhao","year":"2024","unstructured":"Zhao L, Pang Y, Zhou Y, Chen J, Fu H, Guo W, et al. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint Blockade. Signal Transduct Target Ther. 2024;9:142. https:\/\/doi.org\/10.1038\/s41392-024-01853-w.","journal-title":"Signal Transduct Target Ther"},{"key":"2700_CR86","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.2967\/jnumed.123.265763","volume":"64","author":"M Grkovski","year":"2023","unstructured":"Grkovski M, O\u2019Donoghue JA, Imber BS, Andl G, Tu C, Lafontaine D, et al. Lesion dosimetry for [177Lu]Lu-PSMA-617 radiopharmaceutical therapy combined with stereotactic body radiotherapy in patients with oligometastatic Castration-Sensitive prostate cancer. J Nuclear Med Soc Nuclear Med. 2023;64:1779\u201387. https:\/\/doi.org\/10.2967\/jnumed.123.265763.","journal-title":"J Nuclear Med Soc Nuclear Med"},{"key":"2700_CR87","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/pharmaceutics11090450","volume":"11","author":"C M\u00fcller","year":"2019","unstructured":"M\u00fcller C, De Prado Leal M, Dominietto MD, Umbricht CA, Safai S, Perrin RL, et al. Combination of proton therapy and radionuclide therapy in mice: preclinical pilot study at the Paul scherrer Institute. Pharmaceutics. Multidisciplinary Digit Publishing Inst. 2019;11:450. https:\/\/doi.org\/10.3390\/pharmaceutics11090450.","journal-title":"Multidisciplinary Digit Publishing Inst"},{"key":"2700_CR88","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1007\/s00259-021-05236-z","volume":"48","author":"S Nicolini","year":"2021","unstructured":"Nicolini S, Bodei L, Bongiovanni A, Sansovini M, Grassi I, Ibrahim T, et al. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2021;48:3260\u20137. https:\/\/doi.org\/10.1007\/s00259-021-05236-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2700_CR89","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","volume":"24","author":"R Aggarwal","year":"2023","unstructured":"Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, et al. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol Elsevier. 2023;24:1266\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(23)00451-5.","journal-title":"Lancet Oncol Elsevier"},{"key":"2700_CR90","doi-asserted-by":"publisher","unstructured":"Sim\u00f3n M, J\u00f8rgensen JT, Khare HA, Christensen C, Nielsen CH, Kjaer A. Combination of [177Lu]Lu-DOTA-TATE targeted radionuclide therapy and photothermal therapy as a promising approach for cancer treatment. Vivo studies in a human xenograft mouse Model. Pharmaceutics, vol. 14. Multidisciplinary Digital Publishing Institute; 2022. p. 1284. https:\/\/doi.org\/10.3390\/pharmaceutics14061284.","DOI":"10.3390\/pharmaceutics14061284"},{"key":"2700_CR91","doi-asserted-by":"publisher","first-page":"e000980","DOI":"10.1136\/jitc-2020-000980","volume":"8","author":"C Kim","year":"2020","unstructured":"Kim C, Liu SV, Subramaniam DS, Torres T, Loda M, Esposito G, et al. Phase I study of the 177Lu-DOTA0-Tyr3-octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J ImmunoTher Cancer. 2020;8:e000980. https:\/\/doi.org\/10.1136\/jitc-2020-000980.","journal-title":"J ImmunoTher Cancer"},{"key":"2700_CR92","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13550-024-01135-0","volume":"14","author":"J Cheng","year":"2024","unstructured":"Cheng J, Zink J, O\u2019Neill E, Cornelissen B, Nonnekens J, Livieratos L, et al. Enhancing [177Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics. EJNMMI Res. 2024;14:73. https:\/\/doi.org\/10.1186\/s13550-024-01135-0.","journal-title":"EJNMMI Res"},{"key":"2700_CR93","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.3390\/cancers15092409","volume":"15","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xu T, Vorobyeva A, Loftenius A, Bodenko V, Orlova A, et al. Radionuclide therapy of HER2-Expressing xenografts using [177Lu]Lu-ABY-027 affibody molecule alone and in combination with trastuzumab. Cancers Multidisciplinary Digit Publishing Inst. 2023;15:2409. https:\/\/doi.org\/10.3390\/cancers15092409.","journal-title":"Cancers Multidisciplinary Digit Publishing Inst"},{"key":"2700_CR94","unstructured":"Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001). J Clin Oncol. https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2023.41.6_suppl.TPS271. Accessed 26 Mar 2025.\u00a0Cited 2025 Mar 26."},{"key":"2700_CR95","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269252","author":"L Kostos","year":"2025","unstructured":"Kostos L, Buteau JP, Kong G, Tran B, Haskali MB, Fahey M, et al. Clinical trial protocol for lucab: A phase I-II trial evaluating Cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients with metastatic Castration-Resistant prostate cancer. J Nucl Med. 2025. https:\/\/doi.org\/10.2967\/jnumed.124.269252. jnumed.124.269252.","journal-title":"J Nucl Med"},{"key":"2700_CR96","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.3390\/cancers15174239","volume":"15","author":"T Mohajershojai","year":"2023","unstructured":"Mohajershojai T, Spangler D, Chopra S, Frejd FY, Yazaki PJ, Nestor M. Enhanced therapeutic effects of 177Lu-DOTA-M5A in combination with heat shock protein 90 inhibitor onalespib in colorectal cancer xenografts. Cancers Multidisciplinary Digit Publishing Inst. 2023;15:4239. https:\/\/doi.org\/10.3390\/cancers15174239.","journal-title":"Cancers Multidisciplinary Digit Publishing Inst"},{"key":"2700_CR97","unstructured":"LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2023.41.16_suppl.5005. Accessed 26 Mar 2025.\u00a0Cited 2025 Mar 26."},{"key":"2700_CR98","doi-asserted-by":"publisher","unstructured":"Aljubran A, Badran A, Alrowaily M, Raef H, Alzahrani AM, Almuhaideb A, et al. Efficacy of everolimus combined with 177Lu-dotatate in the treatment of neuroendocrine tumors. Cancer biotherapy and radiopharmaceuticals, vol. 39. Mary Ann Liebert, Inc., publishers; 2024. p. 164\u20138. https:\/\/doi.org\/10.1089\/cbr.2022.0043.","DOI":"10.1089\/cbr.2022.0043"},{"key":"2700_CR99","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.bj.2024.100744","volume":"47","author":"J-R Tseng","year":"2024","unstructured":"Tseng J-R, Hsu C-L, Hsieh H-H, Ho K-C, Chung Y-H, Wu C-Y. The synergy of 177Lu-FAPI-46 with tyrosine kinase inhibitor in a sarcoma patient-derived xenograft mouse model. Biomedical J. 2024;47:100744. https:\/\/doi.org\/10.1016\/j.bj.2024.100744.","journal-title":"Biomedical J"},{"key":"2700_CR100","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2967\/jnmt.119.237354","volume":"48","author":"A Adnan","year":"2020","unstructured":"Adnan A, Basu S. Combined 177Lu-DOTATATE peptide receptor radionuclide therapy and Platinum-Based chemotherapy in Recurrent, metastatic sinonasal neuroendocrine carcinoma: A promising therapeutic option. J Nuclear Med Technol Soc Nuclear Med. 2020;48:292\u20134. https:\/\/doi.org\/10.2967\/jnmt.119.237354.","journal-title":"J Nuclear Med Technol Soc Nuclear Med"},{"key":"2700_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2022.02.021","volume":"344","author":"AS Timin","year":"2022","unstructured":"Timin AS, Postovalova AS, Karpov TE, Antuganov D, Bukreeva AS, Akhmetova DR, et al. Calcium carbonate carriers for combined chemo- and radionuclide therapy of metastatic lung cancer. J Controlled Release. 2022;344:1\u201311. https:\/\/doi.org\/10.1016\/j.jconrel.2022.02.021.","journal-title":"J Controlled Release"},{"key":"2700_CR102","doi-asserted-by":"publisher","unstructured":"Cytryniak A, Nazaruk E, Bilewicz R, G\u00f3rzy\u0144ska E, \u017belechowska-Matysiak K, Walczak R, et al. Lipidic Cubic-Phase nanoparticles (Cubosomes) loaded with doxorubicin and labeled with 177Lu as a potential tool for combined chemo and internal radiotherapy for Cancers. Nanomaterials, vol 10. Multidisciplinary Digital Publishing Institute; 2020. p. 2272. https:\/\/doi.org\/10.3390\/nano10112272.","DOI":"10.3390\/nano10112272"},{"key":"2700_CR103","doi-asserted-by":"publisher","first-page":"e010212","DOI":"10.1136\/jitc-2024-010212","volume":"13","author":"J Chen","year":"2025","unstructured":"Chen J, Zhou Y, Pang Y, Fu K, Luo Q, Sun L, et al. FAP-targeted radioligand therapy with 68Ga\/177Lu-DOTA-2P(FAPI)2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy. J Immunother Cancer. 2025;13:e010212. https:\/\/doi.org\/10.1136\/jitc-2024-010212.","journal-title":"J Immunother Cancer"},{"key":"2700_CR104","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s00259-020-05054-9","volume":"48","author":"P Guzik","year":"2021","unstructured":"Guzik P, Siwowska K, Fang H-Y, Cohrs S, Bernhardt P, Schibli R, et al. Promising potential of [177Lu]Lu-DOTA-folate to enhance tumor response to immunotherapy\u2014a preclinical study using a syngeneic breast cancer model. Eur J Nucl Med Mol Imaging. 2021;48:984\u201394. https:\/\/doi.org\/10.1007\/s00259-020-05054-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2700_CR105","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12951-021-01083-0","volume":"19","author":"X Shi","year":"2021","unstructured":"Shi X, Li Q, Zhang C, Pei H, Wang G, Zhou H, et al. Semiconducting polymer nano-radiopharmaceutical for combined radio-photothermal therapy of pancreatic tumor. J Nanobiotechnol. 2021;19:337. https:\/\/doi.org\/10.1186\/s12951-021-01083-0.","journal-title":"J Nanobiotechnol"},{"key":"2700_CR106","doi-asserted-by":"publisher","first-page":"12244","DOI":"10.3390\/cimb46110727","volume":"46","author":"MA Kouri","year":"2024","unstructured":"Kouri MA, Georgopoulos A, Manios GE, Maratou E, Spathis A, Chatziioannou S, et al. Preliminary study on Lutetium-177 and gold nanoparticles: apoptosis and radiation enhancement in hepatic cancer cell line. Curr Issues Mol Biol. 2024;46:12244\u201359. https:\/\/doi.org\/10.3390\/cimb46110727.","journal-title":"Curr Issues Mol Biol"},{"key":"2700_CR107","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/bs.podrm.2018.11.001","volume":"44","author":"FY Alqahtani","year":"2019","unstructured":"Alqahtani FY, Aleanizy FS, El Tahir E, Alkahtani HM, AlQuadeib BT, Paclitaxel. Profiles Drug Subst Excip Relat Methodol. 2019;44:205\u201338. https:\/\/doi.org\/10.1016\/bs.podrm.2018.11.001.","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"2700_CR108","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1023\/A:1008215213739","volume":"9","author":"J Lokich","year":"1998","unstructured":"Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol. 1998;9:13\u201321. https:\/\/doi.org\/10.1023\/A:1008215213739.","journal-title":"Ann Oncol"},{"key":"2700_CR109","doi-asserted-by":"publisher","unstructured":"Cortes JE, Pazdur R. Docetaxel. JCO. Wolters K; 1995;13:2643\u201355. https:\/\/doi.org\/10.1200\/JCO.1995.13.10.2643.","DOI":"10.1200\/JCO.1995.13.10.2643"},{"key":"2700_CR110","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2967\/jnmt.119.237354","volume":"48","author":"A Adnan","year":"2020","unstructured":"Adnan A, Basu S. Combined 177Lu-DOTATATE peptide receptor radionuclide therapy and platinum-based chemotherapy in recurrent, metastatic sinonasal neuroendocrine carcinoma: a promising therapeutic option. J Nucl Med Technol. 2020;48:292\u20134. https:\/\/doi.org\/10.2967\/jnmt.119.237354.","journal-title":"J Nucl Med Technol"},{"key":"2700_CR111","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.3390\/jcm13164585","volume":"13","author":"O K\u0131n\u0131ko\u011flu","year":"2024","unstructured":"K\u0131n\u0131ko\u011flu O, \u00d6ven BB, \u00c7elik S, Alan Sel\u00e7uk N, Beyda\u011f\u0131 G, Ak\u00e7ay K, et al. Investigating combination therapy: the role of Lutetium-177 PSMA-617 radioligand therapy and androgen receptor pathway inhibitors in metastatic Castration-Resistant prostate cancer. JCM. 2024;13:4585. https:\/\/doi.org\/10.3390\/jcm13164585.","journal-title":"JCM"},{"key":"2700_CR112","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","volume":"3","author":"F Korell","year":"2022","unstructured":"Korell F, Berger TR, Maus MV. Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes. Med Elsevier. 2022;3:538\u201364. https:\/\/doi.org\/10.1016\/j.medj.2022.05.001.","journal-title":"Med Elsevier"},{"key":"2700_CR113","doi-asserted-by":"publisher","first-page":"k3529","DOI":"10.1136\/bmj.k3529","volume":"362","author":"X Shen","year":"2018","unstructured":"Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. Br Med J Publishing Group. 2018;362:k3529. https:\/\/doi.org\/10.1136\/bmj.k3529.","journal-title":"Br Med J Publishing Group"},{"key":"2700_CR114","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3390\/pharmaceutics15010128","volume":"15","author":"CP Kerr","year":"2023","unstructured":"Kerr CP, Grudzinski JJ, Nguyen TP, Hernandez R, Weichert JP, Morris ZS. Developments in combining targeted radionuclide therapies and immunotherapies for cancer treatment. Pharm Multidisciplinary Digit Publishing Inst. 2023;15:128. https:\/\/doi.org\/10.3390\/pharmaceutics15010128.","journal-title":"Pharm Multidisciplinary Digit Publishing Inst"},{"key":"2700_CR115","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1158\/1078-0432.CCR-21-4332","volume":"28","author":"SC Kleinendorst","year":"2022","unstructured":"Kleinendorst SC, Oosterwijk E, Bussink J, Westdorp H, Konijnenberg MW, Heskamp S. Combining targeted radionuclide therapy and immune checkpoint Inhibition for cancer treatment. Clin Cancer Res. 2022;28:3652\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4332.","journal-title":"Clin Cancer Res"},{"key":"2700_CR116","doi-asserted-by":"publisher","first-page":"396","DOI":"10.2967\/jnumed.121.262344","volume":"63","author":"J Ferdinandus","year":"2022","unstructured":"Ferdinandus J, Fendler WP, Lueckerath K, Berliner C, Kurzidem S, Hadaschik E, et al. Response to combined peptide receptor radionuclide therapy and checkpoint immunotherapy with ipilimumab plus nivolumab in metastatic Merkel cell carcinoma. J Nucl Med. 2022;63:396\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.262344.","journal-title":"J Nucl Med"},{"key":"2700_CR117","doi-asserted-by":"publisher","first-page":"e010212","DOI":"10.1136\/jitc-2024-010212","volume":"13","author":"J Chen","year":"2025","unstructured":"Chen J, Zhou Y, Pang Y, Fu K, Luo Q, Sun L, et al. FAP-targeted radioligand therapy with 68Ga\/177Lu-DOTA-2P(FAPI)2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy. J Immunother Cancer BMJ Specialist Journals. 2025;13:e010212. https:\/\/doi.org\/10.1136\/jitc-2024-010212.","journal-title":"J Immunother Cancer BMJ Specialist Journals"},{"key":"2700_CR118","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.7150\/thno.93249","volume":"14","author":"D Arbuznikova","year":"2024","unstructured":"Arbuznikova D, Klotsotyra A, Uhlmann L, Domogalla L-C, Steinacker N, Mix M, et al. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside. Theranostics. 2024;14:2560\u201372. https:\/\/doi.org\/10.7150\/thno.93249.","journal-title":"Theranostics"},{"key":"2700_CR119","doi-asserted-by":"publisher","first-page":"e13109","DOI":"10.1111\/jne.13109","volume":"34","author":"J Fu","year":"2022","unstructured":"Fu J, Qiu F, Stolniceanu CR, Yu F, Zang S, Xiang Y, et al. Combined use of177 Lu-DOTATATE peptide receptor radionuclide therapy and fluzoparib for treatment of well\u2010differentiated neuroendocrine tumors: A preclinical study. J Neuroendocrinol. 2022;34:e13109. https:\/\/doi.org\/10.1111\/jne.13109.","journal-title":"J Neuroendocrinol"},{"key":"2700_CR120","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1007\/s00259-024-06844-1","volume":"51","author":"H Rauch","year":"2024","unstructured":"Rauch H, Kitzberger C, Janghu K, Hawarihewa P, Nguyen NT, Min Y, et al. Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2024;51:4099\u2013110. https:\/\/doi.org\/10.1007\/s00259-024-06844-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2700_CR121","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","volume":"41","author":"S Sandhu","year":"2023","unstructured":"Sandhu S, Joshua AM, Emmett L, Crumbaker M, Bressel M, Huynh R, et al. LuPARP: phase 1 trial of 177Lu-PSMA-617 and Olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). JCO. 2023;41:5005\u20135005. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.5005.","journal-title":"JCO"},{"key":"2700_CR122","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13550-016-0163-1","volume":"6","author":"M Rusckowski","year":"2016","unstructured":"Rusckowski M, Wang Y, Blankenberg FG, Levashova Z, Backer MV, Backer JM. Targeted scVEGF\/177Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy. EJNMMI Res. 2016;6:4. https:\/\/doi.org\/10.1186\/s13550-016-0163-1.","journal-title":"EJNMMI Res"},{"key":"2700_CR123","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.3390\/cancers13092103","volume":"13","author":"S Sabatasso","year":"2021","unstructured":"Sabatasso S, Fernandez-Palomo C, Hlushchuk R, Fazzari J, Tschanz S, Pellicioli P, et al. Transient and efficient vascular permeability window for adjuvant drug delivery triggered by microbeam radiation. Cancers (Basel). 2021;13:2103. https:\/\/doi.org\/10.3390\/cancers13092103.","journal-title":"Cancers (Basel)"},{"key":"2700_CR124","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3390\/molecules29051030","volume":"29","author":"E-A Salvanou","year":"2024","unstructured":"Salvanou E-A, Kolokithas-Ntoukas A, Prokopiou D, Theodosiou M, Efthimiadou E, Ko\u017ami\u0144ski P, et al. 177Lu-Labeled iron oxide nanoparticles functionalized with doxorubicin and bevacizumab as nanobrachytherapy agents against breast cancer. Molecules. 2024;29:1030. https:\/\/doi.org\/10.3390\/molecules29051030.","journal-title":"Molecules"},{"key":"2700_CR125","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","volume":"40","author":"S Sandhu","year":"2022","unstructured":"Sandhu S, Joshua AM, Emmett L, Spain LA, Horvath L, Crumbaker M, et al. PRINCE: phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol Wolters Kluwer. 2022;40:5017\u20135017. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.5017.","journal-title":"J Clin Oncol Wolters Kluwer"},{"key":"2700_CR126","unstructured":"Clinical Nuclear Medicine. https:\/\/journals.lww.com\/nuclearmed\/abstract\/2017\/11000\/concomitant_177lu_dotatate_and_capecitabine.26.aspx. Accessed 24 Oct 2025.\u00a0Cited 2025 Oct 24."},{"key":"2700_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2023.1218670","author":"SC George","year":"2023","unstructured":"George SC, Samuel EJJ. Developments in 177Lu-based radiopharmaceutical therapy and dosimetry. Front Chem [Internet] Front. 2023. https:\/\/doi.org\/10.3389\/fchem.2023.1218670. [cited 2025 Oct 27];11.","journal-title":"Front Chem [Internet] Front"},{"key":"2700_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1059122","author":"L Kostos","year":"2022","unstructured":"Kostos L, Buteau JP, Yeung T, Iulio JD, Xie J, Cardin A, et al. AlphaBet: combination of radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol). Front Med [Internet] Front. 2022. https:\/\/doi.org\/10.3389\/fmed.2022.1059122. [cited 2025 Oct 27];9.","journal-title":"Front Med [Internet] Front"},{"key":"2700_CR129","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1159\/000434723","volume":"103","author":"PG Claringbold","year":"2016","unstructured":"Claringbold PG, Turner JH. Pancreatic neuroendocrine tumor control: durable objective response to Combination177Lu-Octreotate-Capecitabine-Temozolomide radiopeptide chemotherapy. Neuroendocrinology. 2016;103:432\u20139. https:\/\/doi.org\/10.1159\/000434723.","journal-title":"Neuroendocrinology"},{"key":"2700_CR130","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2013dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(24)00701-3.","journal-title":"Lancet"},{"key":"2700_CR131","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.7150\/thno.98053","volume":"14","author":"A Akhavanallaf","year":"2024","unstructured":"Akhavanallaf A, Joshi S, Mohan A, Worden FP, Krauss JC, Zaidi H, et al. Enhancing precision: A predictive model for 177Lu-DOTATATE treatment response in neuroendocrine tumors using quantitative 68Ga-DOTATATE PET and clinicopathological biomarkers. Theranostics Ivyspring Int Publisher. 2024;14:3708\u201318. https:\/\/doi.org\/10.7150\/thno.98053.","journal-title":"Theranostics Ivyspring Int Publisher"},{"key":"2700_CR132","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus Cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23:1389\u201397. https:\/\/doi.org\/10.1016\/S1470-2045(22)00605-2.","journal-title":"Lancet Oncol"},{"key":"2700_CR133","doi-asserted-by":"publisher","first-page":"1583168","DOI":"10.3389\/fonc.2025.1583168","volume":"15","author":"H Beltran","year":"2025","unstructured":"Beltran H, Calais J, Emmett L, Kuo PH, Logothetis CJ. Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer. Front Oncol. 2025;15:1583168. https:\/\/doi.org\/10.3389\/fonc.2025.1583168.","journal-title":"Front Oncol"},{"key":"2700_CR134","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13550-025-01284-w","volume":"15","author":"H Sung","year":"2025","unstructured":"Sung H, Bae S, Suh M, Choi H, Im H-J, Cheon GJ, et al. Blood-based transcriptomic biomarkers for response to [177Lu]Lu-DOTA-TATE therapy in neuroendocrine tumors. EJNMMI Res. 2025;15:100. https:\/\/doi.org\/10.1186\/s13550-025-01284-w.","journal-title":"EJNMMI Res"},{"key":"2700_CR135","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of 177Lu-PSMA-617 in metastatic Castration-Resistant prostate cancer: correlations between pretherapeutic imaging and Whole-Body tumor dosimetry with treatment outcomes. J Nuclear Med Soc Nuclear Med. 2019;60:517\u201323. https:\/\/doi.org\/10.2967\/jnumed.118.219352.","journal-title":"J Nuclear Med Soc Nuclear Med"},{"key":"2700_CR136","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2967\/jnumed.123.266167","volume":"64","author":"O Sartor","year":"2023","unstructured":"Sartor O, Ledet E, Huang M, Schwartz J, Lieberman A, Lewis B, et al. Prediction of resistance to 177Lu-PSMA therapy by assessment of baseline Circulating tumor DNA biomarkers. J Nuclear Med Soc Nuclear Med. 2023;64:1721\u20135. https:\/\/doi.org\/10.2967\/jnumed.123.266167.","journal-title":"J Nuclear Med Soc Nuclear Med"},{"key":"2700_CR137","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76224","author":"S Moghrabi","year":"2024","unstructured":"Moghrabi S, Al-Houwari R, Ruzzeh S, Al-Ibraheem A. Therapeutic challenges in metastatic Castration-Resistant prostate cancer: A case study and review of prostate-Specific membrane Antigen-Targeted therapy failures in highly prostate-Specific membrane Antigen-Avid disease. Cureus [Internet]. 2024. https:\/\/doi.org\/10.7759\/cureus.76224. [cited 2025 Mar 28].","journal-title":"Cureus [Internet]"},{"key":"2700_CR138","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.nucmedbio.2021.03.006","volume":"96\u201397","author":"W Delbart","year":"2021","unstructured":"Delbart W, Ghanem GE, Karfis I, Flamen P, Wimana Z. Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE in a panel of cancer cell lines. Nucl Med Biol. 2021;96\u201397:68\u201379. https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.03.006.","journal-title":"Nucl Med Biol"},{"key":"2700_CR139","doi-asserted-by":"publisher","first-page":"117050","DOI":"10.1016\/j.ejmech.2024.117050","volume":"282","author":"Q Wang","year":"2025","unstructured":"Wang Q, Li Z, Huang Y, Li C, Li Y, Peng Y, et al. A novel androgen-independent Radiotracer with dual targeting of NTSR1 and PSMA for PET\/CT imaging of prostate cancer. Eur J Med Chem. 2025;282:117050. https:\/\/doi.org\/10.1016\/j.ejmech.2024.117050.","journal-title":"Eur J Med Chem"},{"key":"2700_CR140","doi-asserted-by":"publisher","first-page":"btaf429","DOI":"10.1093\/bioinformatics\/btaf429","volume":"41","author":"P-Y Libouban","year":"2025","unstructured":"Libouban P-Y, Parisel C, Song M, Aci-S\u00e8che S, G\u00f3mez-Tamayo JC, Tresadern G, et al. Spatio-temporal learning from molecular dynamics simulations for protein\u2013ligand binding affinity prediction. Bioinformatics. 2025;41:btaf429. https:\/\/doi.org\/10.1093\/bioinformatics\/btaf429.","journal-title":"Bioinformatics"},{"key":"2700_CR141","doi-asserted-by":"publisher","first-page":"767","DOI":"10.7150\/thno.79806","volume":"13","author":"Q Sun","year":"2023","unstructured":"Sun Q, Li J, Ding Z, Liu Z. Radiopharmaceuticals heat anti-tumor immunity. Theranostics. 2023;13:767\u201386. https:\/\/doi.org\/10.7150\/thno.79806.","journal-title":"Theranostics"},{"key":"2700_CR142","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4103\/jmss.jmss_54_23","volume":"14","author":"B Behmanesh","year":"2024","unstructured":"Behmanesh B, Abdi-Saray A, Deevband MR, Amoui M, Haghighatkhah HR, Shalbaf A. Predicting the response of patients treated with 177Lu-DOTATATE using single-photon emission computed tomography\u2013computed tomography image-based radiomics and clinical features. J Med Signals Sens. 2024;14:28. https:\/\/doi.org\/10.4103\/jmss.jmss_54_23.","journal-title":"J Med Signals Sens"},{"key":"2700_CR143","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3390\/cells14181464","volume":"14","author":"R Coppo","year":"2025","unstructured":"Coppo R, Inoue M. Patient-derived tumor organoids to model cancer cell plasticity and overcome therapeutic resistance. Cells. 2025;14:1464. https:\/\/doi.org\/10.3390\/cells14181464.","journal-title":"Cells"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02700-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02700-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02700-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:48:21Z","timestamp":1776926901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02700-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":143,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2700"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02700-x","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a systematic literature review; therefore, no ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This is a systematic literature review; therefore, no participant consent is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}